Boston Scientific to acquire Penumbra in $14.5B deal, expanding vascular thrombectomy reach
Boston Scientific announced a cash-and-stock deal to acquire Penumbra for about $14.5 billion (Penumbra at $374 per share), expanding its cardiovascular portfolio with Penumbra’s mechanical thrombectomy and neurovascular tech. The transaction is ~73% cash and ~27% stock, financed with cash on hand and new debt, and is expected to close in 2026 after shareholder and regulatory approvals. Penumbra’s 2025 revenue is about $1.4 billion; the deal aims to broaden access to vascular therapies and drive long-term growth, though GAAP earnings are expected to be dilutive in the near term.
